江汉大学图书馆书目检索系统

Online Public Access Catalogue

题名/责任者:

Bioinorganic chemistry : a short course / Rosette M. Roat-Malone, Washington College, Chestertown, MD.

版本说明:

Third edition.

出版发行项:

Hoboken, NJ : Wiley, 2019.

ISBN:

9781119535218

载体形态项:

352 pages ; 24 cm

个人责任者:

Roat-Malone, Rosette M., author.

论题主题:

Bioinorganic chemistry.

中图法分类号:

Q5

书目附注:

Includes bibliographical references and index.

内容附注:

Machine generated contents note: 1.Inorganic Chemistry And Biochemistry Essentials -- 1.1.Introduction -- 1.2.Essential Chemical Elements -- 1.3.Inorganic Chemistry Basics -- 1.4.Electronic and Geometric Structures of Metals in Biological Systems -- 1.5.Thermodynamics and Kinetics -- 1.6.Bioorganometallic Chemistry -- 1.7.Inorganic Chemistry Conclusions -- 1.8.Introduction to Biochemistry -- 1.9.Proteins -- 1.9.1.Amino Acid Building Blocks -- 1.9.2.Protein Structure -- 1.9.3.Protein Function, Enzymes, and Enzyme Kinetics -- 1.10.DNA and RNA Building Blocks -- 1.10.1.DNA and RNA Molecular Structures -- 1.10.2.Transmission of Genetic Information -- 1.10.3.Genetic Mutations and Site-Directed Mutagenesis -- 1.10.4.Genes and Cloning -- 1.10.5.Genomics and the Human Genome -- 1.10.6.CRISPR -- 1.11.A Descriptive Example: Electron Transport Through DNA -- 1.11.1.Cyclic Voltammetry -- 1.12.Summary and Conclusions -- 1.13.Questions and Thought Problems -- References -- 2.Computer Hardware, Software, And Computational Chemistry Methods -- 2.1.Introduction to Computer-Based Methods -- 2.2.Computer Hardware -- 2.3.Computer Software for Chemistry -- 2.3.1.Chemical Drawing Programs -- 2.3.2.Visualization Programs -- 2.3.3.Computational Chemistry Software -- 2.3.3.1.Molecular Dynamics (MD) Software -- 2.3.3.2.Mathematical and Graphing Software -- 2.4.Molecular Mechanics (MM), Molecular Modeling, and Molecular Dynamics (MD) -- 2.5.Quantum Mechanics-Based Computational Methods -- 2.5.1.Ab-initio Methods -- 2.5.2.Semiempirical Methods -- 2.5.3.Density Functional Theory and Examples -- 2.5.3.1.Starting with Schrodinger -- 2.5.3.2.Density Functional Theory (DFT) -- 2.5.3.3.Basis Sets -- 2.5.3.4.DFT Applications -- 2.5.4.Quantum Mechanics/Molecular Mechanics (QM/MM) Methods -- 2.6.Conclusions on Hardware, Software, and Computational Chemistry -- 2.7.Databases, Visualization Tools, Nomenclature, and other Online Resources -- 2.8.Questions and Thought Problems -- References -- 3.Important Metal Centers In Proteins -- 3.1.Iron Centers in Myoglobin and Hemoglobin -- 3.1.1.Introduction -- 3.1.2.Structure and Function as Determined by X-ray Crystallography and Nuclear Magnetic Resonance -- 3.1.3.Cryo-Electron Microscopy and Hemoglobin Structure/Function -- 3.1.3.1.Introduction -- 3.1.3.2.Cryo-Electron Microscopy Techniques -- 3.1.3.3.Structures Determined Using Cryo-Electron Microscopy -- 3.1.4.Model Compounds -- 3.1.5.Blood Substitutes -- 3.2.Iron Centers in Cytochromes -- 3.2.1.Cytochrome c Oxidase -- 3.2.2.Cytochrome c Oxidase (CcO) Structural Studies -- 3.2.3.Cytochrome c Oxidase (CcO) Catalytic Cycle and Energy Considerations -- 3.2.4.Proton Channels in Cytochrome c Oxidase -- 3.2.5.Cytochrome c Oxidase Model Compounds -- 3.3.Iron-Sulfur Clusters in Nitrogenase -- 3.3.1.Introduction -- 3.3.2.Nitrogenase Structure and Catalytic Mechanism -- 3.3.3.Mechanism of Dinitrogen (N2) Reduction -- 3.3.4.Substrate Pathways into Nitrogenase -- 3.3.5.Nitrogenase Model Compounds -- 3.3.5.1.Functional Nitrogenase Models -- 3.3.5.2.Structural Nitrogenase Models -- 3.4.Copper and Zinc in Superoxide Dismutase -- 3.4.1.Introduction -- 3.4.2.Superoxide Dismutase Structure and Mechanism of Catalytic Activity -- 3.4.3.A Copper Zinc Superoxide Dismutase Model Compound -- 3.5.Methane Monooxygenase -- 3.5.1.Introduction -- 3.5.2.Soluble Methane Monooxygenase -- 3.5.3.Particulate Methane Monooxygenase -- 3.6.Summary and Conclusions -- 3.7.Questions and Thought Problems -- References -- 4.Hydrogenases, Carbonic Anhydrases, Nitrogen Cycle Enzymes -- 4.1.Introduction -- 4.2.Hydrogenases -- 4.2.1.Introduction -- 4.2.2.[NiFe]-hydrogenases -- 4.2.2.1.[NiFe]-hydrogenase Model Compounds -- 4.2.3.[FeFe]-hydrogenases -- 4.2.3.1.[FeFe]-Hydrogenase Model Compounds -- 4.2.4.[Fe]-hydrogenases -- 4.2.4.1.[Fe]-Hydrogenase Model Compounds -- 4.3.Carbonic Anhydrases -- 4.3.1.Introduction -- 4.3.2.Carbonic Anhydrase Inhibitors -- 4.4.Nitrogen Cycle Enzymes -- 4.4.1.Introduction -- 4.4.2.Nitric Oxide synthase -- 4.4.2.1.Introduction -- 4.4.2.2.Nitric Oxide Synthase Structure -- 4.4.2.3.Nitric Oxide Synthase Inhibitors -- 4.4.3.Nitrite Reductase -- 4.4.3.1.Introduction -- 4.4.3.2.Reduction of Nitrite Ion to Ammonium Ion -- 4.4.3.3.Reduction of Nitrite Ion to Nitric Oxide -- 4.5.Summary and Conclusions -- 4.6.Questions and Thought Problems -- References -- 5.Nanobioinorganic Chemistry -- 5.1.Introduction to Nanomaterials -- 5.2.Analytical Methods -- 5.2.1.Microscopy -- 5.2.1.1.Scanning Electron Microscopy (SEM) -- 5.2.1.2.Transmission Electron Microscopy (TEM) -- 5.2.1.3.Scanning Transmission Electron Microscopy (STEM) -- 5.2.1.4.Cryo-Electron Microscopy -- 5.2.1.5.Scanning Probe Microscopy (SPM) -- 5.2.1.6.Atomic Force Microscopy (AFM) -- 5.2.1.7.Super-Resolution Microscopy and DNA-PAINT -- 5.2.2.Forster Resonance Energy Transfer (FRET) -- 5.3.DNA Origami -- 5.4.Metallized DNA Nanomaterials -- 5.4.1.Introduction -- 5.4.2.DNA-Coated Metal Electrodes -- 5.4.3.Plasmonics and DNA -- 5.5.Bioimaging with Nanomaterials, Nanomedicine, and Cytotoxicity -- 5.5.1.Introduction -- 5.5.2.Imaging with Nanomaterials -- 5.5.3.Bioimaging using Quantum Dots (QD) -- 5.5.4.Nanoparticles in Therapeutic Nanomedicine -- 5.5.4.1.Clinical Nanomedicine -- 5.5.4.2.Some Drugs Formulated into Nanomaterials for Cancer Treatment: Cisplatinum, Platinum(IV) Prodrugs, and Doxorubicin -- 5.6.Theranostics -- 5.7.Nanoparticle Toxicity -- 5.8.Summary and Conclusions -- 5.9.Questions and Thought Problems -- References -- 6.Metals In Medicine, Disease States, Drug Development -- 6.1.Platinum Anticancer Agents -- 6.1.1.Cisplatin -- 6.1.1.1.Cisplatin Toxicity -- 6.1.1.2.Mechanism of Cisplatin Activity -- 6.1.2.Carboplatin (Paraplatin) -- 6.1.3.Oxaliplatin -- 6.1.4.Other cis-Platinum(II) Compounds -- 6.1.4.1.Nedaplatin -- 6.1.4.2.Lobaplatin -- 6.1.4.3.Heptaplatin -- 6.1.5.Antitumor Active Trans Platinum compounds -- 6.1.6.Platinum Drug Resistance -- 6.1.7.Combination Therapies: Platinum-Containing Drugs with Other Antitumor Compounds -- 6.1.8.Platinum(IV) Antitumor Drugs -- 6.1.8.1.Satraplatin -- 6.1.8.2.Ormaplatin -- 6.1.8.3.Iproplatin, JM9, CHIP -- 6.1.9.Platinum(IV) Prodrugs -- 6.1.9.1.Multitargeted Platinum(IV) Prodrugs -- 6.1.9.2.Platinum(IV) Prodrugs Delivered via Nanoparticles -- 6.2.Ruthenium Compounds as Anticancer Agents -- 6.2.1.Ruthenium(III) Anticancer Agents -- 6.2.2.Ruthenium(II) Anticancer Agents -- 6.2.3.Mechanism of Ruthenium(II) Anticancer Agent Activity -- 6.2.4.Ruthenium Compounds Tested for Antitumor Activity -- 6.3.Iridium and Osmium Antitumor Agents -- 6.4.Other Antitumor Agents -- 6.4.1.Gold Complexes -- 6.4.2.Titanium Complexes -- 6.4.3.Copper Complexes -- 6.5.Bismuth Derivatives as Antibacterials -- 6.6.Disease States, Drug Discovery, and Treatments -- 6.6.1.Superoxide Dismutases (SOD) in Disease States -- 6.6.2.Amyotrophic Lateral Sclerosis -- 6.6.3.Wilson's and Menkes Disease -- 6.6.4.Alzheimer's disease -- 6.6.4.1.Role of Amyloid ?2 Protein -- 6.6.4.2.Interactions of A ?2 Peptides with Metals -- 6.6.4.3.Alzheimer's Disease Treatments -- 6.7.Other Disease States Involving Metals -- 6.7.1.Copper and Zinc Ions and Cataract Formation -- 6.7.2.As263, used in the Treatment of Acute Promyelocytic Leukemia (APL) -- 6.7.3.Vanadium-based Type 2 Diabetes Drugs -- 6.8.Summary and Conclusions -- 6.9.Questions and Thought Problems -- References.

豆瓣简介：